Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors
Latest Information Update: 31 May 2024
At a glance
- Drugs Crisantaspase biobetter (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
Most Recent Events
- 23 May 2024 Status changed from active, no longer recruiting to discontinued.
- 28 Feb 2024 Planned End Date changed from 29 Nov 2027 to 29 Nov 2024.
- 28 Feb 2024 Planned primary completion date changed from 29 Nov 2027 to 29 Nov 2024.